AI OverviewFDA meetings, categorized as Type A, Type B, and Type C, are crucial interactions between sponsors and the FDA during drug development. Type A meetings address stalled development or safety issues. Type B meetings are milestone meetings, such as pre-IND or end-of-phase meetings. Type C meetings are for any other development-related topics not covered by A or B.Type A Meetings: These meetings are for resolving critical issues that are actively blocking the progress of a product's development. They are typically held when a product development program is stalled or to address an important safety concern. For example, a Type A meeting might be needed if a clinical hold is preventing further trials.Type B Meetings: These meetings are scheduled around specific milestones in the drug development process. They include:
Pre-IND Meetings:Held before an Investigational New Drug application to discuss the planned clinical trials. End-of-Phase Meetings:Held at the end of specific phases of clinical trials (e.g., End-of-Phase 1) to discuss the next steps in development. Pre-NDA/BLA Meetings:Held before submitting a New Drug Application (NDA) or Biologics License Application (BLA).Type C Meetings: This is a broad category for any meeting that doesn't fall under Type A or Type B. These meetings can cover a wide range of topics, including:
- Discussions on the use of new biomarkers.
- Protocol amendments.
- Data interpretation.
- Early discussions about therapies, trial designs, or data requirements.
In essence, Type A meetings are about getting things moving again, Type B meetings are about reaching specific milestones, and Type C meetings are about addressing a variety of other development-related issues.
Formal FDA Meetings for Sponsors or Applications of PDUFA Products26 Feb 2024 — Types of FDA Meetings * Type A FDA Meetings. Type A FDA meetings are "necessary for an otherwise stalled product devel...ProPharma FDA guidance on formal meetings adds new categories ...21 Sept 2023 — Meeting types. The guidance describes the different meeting categories: Type A, B, C and Type D and INTERACT meetings.RAPSAI responses may include mistakes. Learn more
- Forums
- ASX - By Stock
- IMM
- Merck conundrum
IMM
immutep limited
Add to My Watchlist
0.00%
!
25.5¢

Merck conundrum, page-67
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
25.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $372.3M |
Open | High | Low | Value | Volume |
25.0¢ | 26.5¢ | 25.0¢ | $633.3K | 2.467M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 127753 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.5¢ | 73561 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 125753 | 0.250 |
6 | 174160 | 0.245 |
13 | 316243 | 0.240 |
4 | 177553 | 0.235 |
11 | 413538 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 7774 | 1 |
0.260 | 248526 | 3 |
0.265 | 853745 | 4 |
0.270 | 238750 | 3 |
0.275 | 54000 | 3 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |